Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Biogen Safe HarborThis news release contains forward-looking statements, including, among others, relating to: the potential clinical effects of zorevunersen; the...